var data={"title":"Insulin glulisine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin glulisine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/159766?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-glulisine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin glulisine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=insulin-glulisine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin glulisine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707939\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114407\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Apidra;</li>\n      <li>Apidra SoloStar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934392\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apidra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127492\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Insulin, Rapid-Acting</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127510\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Insulin glulisine is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with an intermediate- or long-acting insulin. When compared to insulin regular, insulin glulisine has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin glulisine may be administered IV. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 1:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Type 1: <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined.</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Initial total insulin dose:</b> 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Usual maintenance range:</b> 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&quot;conventional therapy&quot;):</b> Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting insulin (eg, lispro, aspart, glulisine) or short-acting (regular) form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Division of daily insulin requirement (&quot;intensive therapy&quot;):</b> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short-acting (regular) or rapid-acting insulin (eg, lispro, aspart, glulisine) formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Dose adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Continuous SubQ insulin infusion (insulin pump):</b> A combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Off-label:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Initial:</b> 4 units <b>or</b> 0.1 unit/kg <b>or</b> 10% of the <b>basal</b> insulin dose; insulin glulisine (ie, a rapid acting insulin) is administered before the largest meal of the day and is usually given in addition to a regimen that includes <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) and metformin +/- other noninsulin agents. If HbA<sub>1c</sub> is still not controlled despite titrations to reach glycemic targets, one option is to advance to &lsquo;basal-bolus&rsquo; (ie, insulin glulisine administered before &ge;2 meals per day) in addition to <b>basal</b> insulin and usually given in addition to metformin +/- other noninsulin agent (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosage adjustment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To reach self-monitoring glucose target: Adjust dose by 10% to 15% <b>or</b> 1 to 2 units; may adjust at weekly or twice weekly intervals (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For hypoglycemia: If no clear reason for hypoglycemia, decrease dose by 2 to 4 units <b>or </b>by 10% to 20% (ADA 2017f)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General considerations for insulin use in type 2 diabetes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Timing of initiation:</i> Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months with lifestyle intervention and metformin monotherapy or dual therapy, respectively (unless contraindications to metformin exist). Preference is not given for which agent(s) should be added to metformin (drug choice should be individualized based on patient characteristics). If HbA1c target not achieved after ~3 months of triple therapy, consider initiating basal insulin (usually with metformin +/- other noninsulin agent) or if patient already receiving an optimally titrated <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) as part of their regimen, consider combination injectable therapy (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination injectable therapy:</i> If HbA<sub>1c</sub> target has not been met with <b>basal </b>insulin (ie, long-acting insulin such as glargine, degludec or detemir) (usually combined with metformin +/- other noninsulin agent), despite titrating <b>basal</b> insulin to provide acceptable fasting blood glucose concentrations, combination injectable therapy should be considered. Options include: adding a rapid-acting insulin (eg, lispro, aspart, glulisine) prior to largest meal <b>or</b> adding a GLP-1 receptor agonist <b>or</b> changing from <b>basal </b>insulin to a twice daily premixed insulin. If HbA<sub>1c </sub>still not adequately controlled, consider advancing from one rapid-acting insulin prior to largest meal to &lsquo;basal-bolus&rsquo; regimen (ie, rapid-acting insulin administered before &ge;2 meals) <b>or</b> consider advancing from a twice daily premixed insulin to a three times daily premixed insulin (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients with elevated HbA<sub>1C</sub> at therapy initiation:</i> If HbA<sub>1c</sub> is &ge;9% at initiation of therapy, dual therapy (metformin + a second antihyperglycemic agent) should be considered. If HbA<sub>1c</sub> &ge;10%, blood glucose is &ge;300 mg/dL or if patient is symptomatic (eg, polyuria, polydipsia), insulin therapy (with or without additional agents) should be considered (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperglycemia, critically ill (off-label use):</b> IV continuous infusion: Insulin therapy should be implemented when blood glucose &ge;150 mg/dL with a goal to maintain blood glucose &lt;150 mg/dL (with values absolutely &lt;180 mg/dL) using a protocol that achieves a low rate of hypoglycemia (ie, &le;70 mg/dL). Before discontinuation, stable ICU patients should be transitioned to a protocol-driven basal/bolus insulin regimen, based on insulin infusion history and carbohydrate intake, to avoid loss of glycemic control. Subcutaneous insulin therapy may be considered for selected clinically stable ICU patients (SCCM [Jacobi 2012]). <b>Note:</b> The Surviving Sepsis Campaign guidelines recommend initiating insulin dosing in patients with severe sepsis when 2 consecutive blood glucose concentrations are &gt;180 mg/dL and to target an upper blood glucose &le;180 mg/dL (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic ketoacidosis (off-label use):</b> IV: 0.1 unit/kg bolus, followed by a continuous infusion of 0.1 unit/kg/hour until blood glucose &lt;250 mg/dL, then decrease to 0.05 unit/kg/hour until resolution of ketoacidosis. Discontinue IV infusion 2 hours after administration of subcutaneous insulin (Umpierrez 2009). Also, refer to institution-specific protocols where appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127509\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=insulin-glulisine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin glulisine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Insulin glulisine is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with an intermediate- or long-acting insulin. Insulin glulisine is equipotent to insulin regular, but has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin glulisine may be administered IV in some situations. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General insulin dosing (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Type 1 diabetes mellitus:</b> Children and Adolescents: <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are utilized. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Initial dose:</b> SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapidly acting insulin may be the only insulin formulation used initially.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Usual maintenance range:</b> SubQ: 0.5 to 1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day (IDF/ISPAD, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dose adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Continuous SubQ insulin infusion (insulin pump):</b> A combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer-acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2308005\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127511\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8103886\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330566\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104248\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Apidra: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Apidra SoloStar: 100 units/mL (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127491\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114466\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Insulin glulisine should be administered within 15 minutes before or within 20 minutes after starting a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy. Insulin glulisine from a vial may be mixed with insulin NPH only (do not mix with other types of insulin); insulin glulisine should be drawn into syringe first. Do not mix other insulin formulations with insulin glulisine contained in a cartridge or prefilled pen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CSII administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets, reservoirs, infusion set insertion sites, and the insulin in the reservoir should be changed every 48 hours; rotate infusion sites. Do not dilute or mix other insulin formulations with insulin glulisine that is to be used in an external insulin pump.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. <b>Do not administer insulin mixtures intravenously. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusions: To minimize insulin adsorption to plastic IV tubing: Although data is lacking regarding adsorption with insulin glulisine, insulin regular loss has been shown to occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (SCCM [Jacobi 2012]; Thompson 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Also refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114412\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, types 1 and 2: </b>Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474639\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Diabetic ketoacidosis; Hyperglycemia during critical illness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127488\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Apidra may be confused with Spiriva</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Insulin glulisine may be confused with insulin glargine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale), is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Recommendation pertains to the sole use of short- or rapid-acting insulins in the absence of basal or long-acting insulin; recommendation does not apply to the titration of basal insulin or the use of additional short- or rapid-acting insulin in conjunction with scheduled insulin (ie, correction insulin) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114418\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Severe hypoglycemia (1% to 8%; children and adolescents, type 1 diabetes: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (8% to 11%), upper respiratory tract infection (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (8%; adults, type 2 diabetes), hypertension (4%; adults, type 2 diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7%; children and adolescents, type 1 diabetes), hypoglycemic seizure (6%; children and adolescents, type 1 diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypoglycemia (7%; adults, type 1 diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (6%; adults, type 2 diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (no effect on drug efficacy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hypertrophy at injection site, lipoatrophy at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Catheter complication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127497\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to insulin glulisine or any component of the formulation; during episodes of hypoglycemia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114414\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV use and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen (insulin regular) in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal </b>insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia). A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2017d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin [eg, insulin glulisine]) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient's impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to the short duration of action of insulin glulisine, a longer acting insulin or CSII via an external insulin pump is needed to maintain adequate glucose control in patients with type 1 diabetes mellitus (insulin dependent, IDDM). In both type 1 and type 2 diabetes, preprandial administration of insulin glulisine should be immediately followed by a meal within 15 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CSII administration: May be administered via CSII; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SubQ insulin administration may be required until the problem is identified and corrected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Insulin glulisine may be administered IV in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8103884\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2343861\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9024&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127493\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127494\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">In animal reproduction studies, outcomes were similar to those observed with regular insulin.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2017c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 2013; ADA 2017c; Blumer 2013; Kitzmiller 2008; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ADA 2017c). Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ADA 2017c). However, due to lack of clinical data, insulin glulisine is not currently recommended for use in pregnant women (Blumer 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2114413\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Breastfeeding is encouraged for all women, including those with type 1, type 2, or GDM (ACOG 2005; ADA 2017c; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">All types of insulin may be used while breastfeeding (Metzger 2007). Adjustments of the mother's insulin dose may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8103887\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127512\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Critically ill patients receiving insulin infusion: Blood glucose every 1 to 2 hours. <b>Note:</b> Every 4 hour blood glucose monitoring is not recommended unless a low hypoglycemia rate is demonstrated with the insulin protocol used. Arterial or venous whole blood sampling is recommended for patients in shock, on vasopressor therapy, or with severe edema, and when on a prolonged insulin infusion (SCCM [Jacobi 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Diabetes mellitus: Plasma glucose, electrolytes, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2017a]), renal function, hepatic function, weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration: Close monitoring of blood glucose and serum potassium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127503\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2017a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 20167b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in pediatric (all age groups) patients with type 1 diabetes (ADA 2017e):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (individualization may be appropriate based on patient-specific characteristics; &lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime and overnight capillary blood glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for hospitalized adult patients with diabetes (ADA 2017d): Target glucose range: 140 to 180 mg/dL (majority of critically ill and noncritically ill patients; &lt;140 mg/dL may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at &ge;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for perioperative care in adult patients with diabetes (ADA 2017d): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127502\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin glulisine differs from human insulin by containing a lysine and glutamic acid at positions B3 and B29, respectively, in comparison to the asparagine and lysine found at B3 and B29 in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glulisine is a rapid-acting insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127504\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Onset of action: 0.2-0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 1.6-2.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 3-4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: 13 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 13 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 42 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 60 minutes (range: 40-120 minutes) </p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370385\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Apidra Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $323.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Apidra SoloStar Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $125.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038884\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apidra (AE, AR, AT, AU, BB, BE, BG, BH, BR, BS, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TT, TW, UY, VN);</li>\n      <li>Shorant (CR, DO, GT, HN, MX, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979893\"></a>American Diabetes Association (ADA). 6. Glycemic targets. <i>Diabetes Care</i>. 2017a;40(suppl 1):S48&ndash;S56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979893/pubmed\" target=\"_blank\" id=\"27979893\">27979893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979900\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy. <i>Diabetes Care</i>. 2017c;40(suppl 1):S114-S119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979900/pubmed\" target=\"_blank\" id=\"27979900\">27979900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital. <i>Diabetes Care</i>. 2017d;40(suppl 1):S120&ndash;S127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979901/pubmed\" target=\"_blank\" id=\"27979901\">27979901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Children and adolescents. <i>Diabetes Care</i>. 2017e;40(suppl 1):S105&ndash;S113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979899/pubmed\" target=\"_blank\" id=\"27979899\">27979899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 8. Pharmacologic approaches to glycemic treatment. <i>Diabetes Care.</i> 2017f;40(suppl 1):S64&ndash;S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/27979895/pubmed\" target=\"_blank\" id=\"27979895\">27979895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apidra (insulin glulisine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apidra (insulin glulisine) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Hosp Pharm</i>. 2012;47(5):367-370.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. <i>Am J Hosp Pharm</i>. 1977;34(6):583-588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/406784/pubmed\" target=\"_blank\" id=\"406784\">406784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. <i>Am J Hosp Pharm</i>. 1981;38(7):995-997.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/7020415/pubmed\" target=\"_blank\" id=\"7020415\">7020415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. 2011. Available at http://www.idf.org/e-library/guidelines/80-the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html. Last accessed: October 21, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabchi AE, Umpierrez GE, Miles JM, et al, &ldquo;Hyperglycemic Crises in Adult Patients With Diabetes,&rdquo; <i>Diabetes Care</i>, 2009, 32(7):1335-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/19564476/pubmed\" target=\"_blank\" id=\"19564476\">19564476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabchi AE, Umpierrez GE, Murphy MB, et al, &quot;Hyperglycemic Crises in Diabetes,&rdquo; <i>Diabetes Care</i>, 2004, 27(Suppl 1): 94-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/14693938/pubmed\" target=\"_blank\" id=\"14693938\">14693938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Bircher N, Krinsley J, et al, &ldquo;Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 2012, 40(12):3251-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/23164767/pubmed\" target=\"_blank\" id=\"23164767\">23164767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy.<i> Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/23489521 /pubmed\" target=\"_blank\" id=\"23489521 \">23489521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo; <i>Endocr Pract</i>, 2009, 15(4):353-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/19454396/pubmed\" target=\"_blank\" id=\"19454396\">19454396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19318384\"></a>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, &ldquo;Intensive Versus Conventional Glucose Control in Critically Ill Patients,&rdquo; <i>N Engl J Med</i>, 2009, 360(13):1283-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/19318384 /pubmed\" target=\"_blank\" id=\"19318384 \">19318384 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Diabetes Metab Syndr Obes</i>. 2013;6:389-392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/24143117/pubmed\" target=\"_blank\" id=\"24143117\">24143117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>.2012;14(10):912-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/22746979/pubmed\" target=\"_blank\" id=\"22746979\">22746979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19366972\"></a>Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. <i>Diabetes Care</i>. 2009;32(7):1164-1169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/19366972/pubmed\" target=\"_blank\" id=\"19366972\">19366972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16452557\"></a>van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. <i>N Engl J Med</i>. 2006;354(5):449-461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/16452557/pubmed\" target=\"_blank\" id=\"16452557\">16452557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11794168\"></a>van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. <i>N Engl J Med</i>. 2001;345(19):1359-1367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/11794168/pubmed\" target=\"_blank\" id=\"11794168\">11794168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/22500167 /pubmed\" target=\"_blank\" id=\"22500167 \">22500167 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18728267\"></a>Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. <i>JAMA</i>. 2008;300(8):933-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-glulisine-drug-information/abstract-text/18728267/pubmed\" target=\"_blank\" id=\"18728267\">18728267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo; Pediatr Diabetes, 2007, 8(1):28-43. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5448.2007.00224.x/full17341289</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9024 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707939\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2114407\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934392\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2127492\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2127510\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2127509\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2308005\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2127511\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8103886\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330566\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2104248\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2127491\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2114466\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2114412\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474639\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2127488\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2114418\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2127497\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2114414\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8103884\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2343861\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2127493\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2127494\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2114413\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8103887\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2127512\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2127503\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2127502\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2127504\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370385\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038884\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9024|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-glulisine-patient-drug-information\" class=\"drug drug_patient\">Insulin glulisine: Patient drug information</a></li><li><a href=\"topic.htm?path=insulin-glulisine-pediatric-drug-information\" class=\"drug drug_pediatric\">Insulin glulisine: Pediatric drug information</a></li></ul></div></div>","javascript":null}